PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 23, 2017Journal of Cellular Biochemistry244 citations

Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress

View Full Paper
ABAfsane BahramiMKMajid KhazaeiMHMalihe Hasanzadeh

Key Points

Key points are not available for this paper at this time.

Abstract

PI3K/AKT/mTOR signaling pathway is one of the key dysregulated pathways in different tumor types, including colorectal cancer (CRC). Activation of this pathway is shown to be related with cellular transformation, tumor progression, cell survival, and drug resistance. There is growing body of data evaluating the value of PI3K/AKT/mTOR inhibitors in CRC (e.g., BEZ235, NVP-BEZ235, OSI-027, everolimus, MK-2206, KRX-0401, BYL719, and BKM120). This report summarizes the current knowledge about PI3K/AKT pathway and its cross talk with ERK/MAPK and mTOR pathways with particular emphasis on the value of targeting this pathway as a potential therapeutic target in treatment of colorectal cancer. J. Cell. Biochem. 119: 2460-2469, 2018. © 2017 Wiley Periodicals, Inc.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bahrami et al. (2017) studied this question.

synapsesocial.com/papers/6a72cc803ce530166bc363c4https://doi.org/10.1002/jcb.25950
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High Frequency of Mutations of the PIK3CA Gene in Human Cancers2004 · 3,462 citations
  2. 2Role of Akt signaling in resistance to DNA-targeted therapy2016 · 82 citations
  3. 3A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).1994 · 3,264 citations
  4. 4A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors2012 · 176 citations
  5. 5Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity2008 · 1,153 citations